SCHEMBL1838580

SCHEMBL1838580

N=C(N)NCc1c[nH]c2ncccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 2/20 0.59
MET P08581 1/20 0.52
MTNR1A P48039 1/20 0.52
AXL P30530 1/20 0.45
DRD4 P21917 5/20 0.45
DRD2 P14416 3/20 0.45
DRD3 P35462 3/20 0.45
CAMKK2 Q96RR4 1/20 0.44
FGFR1 P11362 1/20 0.43
FGFR4 P22455 1/20 0.43
ADORA2A P29274 1/20 0.43
CDK2 P24941 2/20 0.43
PDPK1 O15530 1/20 0.43
CCNT1 O60563 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK9 P50750 1/20 0.43
CCNA1 P78396 1/20 0.43
CDK5 Q00535 1/20 0.43
CDK5R1 Q15078 1/20 0.43
LRRK2 Q5S007 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2312816 0.99 GPR84 (0.58) GPR84METMTNR1AAXLDRD4
SCHEMBL27581164 0.85 GPR84 (0.59) GPR84METMTNR1AAXLDRD4
SCHEMBL27033531 0.81 GPR84 (0.61) GPR84METMTNR1AAXLDRD4
SCHEMBL20258623 0.79 MTNR1A (0.62) GPR84METMTNR1AAXLDRD4
SCHEMBL2217980 0.77 GPR84 (0.76) GPR84METMTNR1AAXLDRD4
Hydrochloric Acid SCHEMBL538973 0.77 PRKCI (0.42) AXLFGFR1CDK9CDK5LRRK2
SCHEMBL7998339 0.76 MET (0.63) GPR84METMTNR1ADRD4DRD2
SCHEMBL1836680 0.76 GPR84 (0.73) GPR84METMTNR1AAXLDRD4
SCHEMBL2981093 0.76 GPR84 (0.63) GPR84METMTNR1AAXLDRD4
SCHEMBL27911675 0.76 GPR84 (1.00) GPR84METMTNR1AAXLDRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 GPR84 3398/4885MET 1761/4885MTNR1A 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.